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Objectives: Against a backdrop of rising levels of
obesity, we describe and estimate associations of body
mass index (BMI), age and gender with time to
revision for participants undergoing primary total hip
(THR) or knee (TKR) replacement in the UK.
Design: Population-based cohort study.
Setting: Routinely collected primary care data from a
representative sample of general practices, including
linked data on all secondary care events.
Participants: Population-based cohort study of
63 162 patients with THR and 54 276 with TKR in the
UK General Practice Research Database between 1988
and 2011.
Primary and secondary outcomes: Risk of
THR and TKR revision associated with BMI, age
and gender, after adjusting for the competing risk of
death.
Results: The 5-year cumulative incidence rate for THR
was 2.2% for men and 1.8% for women (TKR 2.3%
for men, 1.6% for women). The adjusted overall
subhazard ratio (SHR) for patients with THR
undergoing subsequent hip revision surgery, with a
competing risk of death, were estimated at 1.020 (95%
CI 1.009 to 1.032) per additional unit (kg/m2) of BMI,
1.23 (95% CI 1.10 to 1.38) for men compared with
women and 0.970 (95% CI 0.967 to 0.973) per
additional year of age. For patients with TKR, the
equivalent estimates were 1.015 (95% CI 1.002 to
1.028) for BMI; 1.51 (95% CI 1.32 to 1.73) for gender
and 0.957 (95% CI 0.951 to 0.962) for age. Morbidly
obese patients with THR had a 65.5% increase (95%
CI 15.4% to 137.3%, p=0.006) in the subhazard of
revision versus the normal BMI group (18.5–25). The
effect for TKR was smaller (a 43.9% increase) and
weaker (95% CI 2.6% to 103.9%, p=0.040).
Conclusions: BMI is estimated to have a small but
statistically significant association with the risk of hip
and knee revision, but absolute numbers are small.
Further studies are needed in order to distinguish
between effects for specific revision surgery
indications.
INTRODUCTION
Total joint replacement of the hip and knee
are well established as interventions for those
suffering with end-stage osteoarthritis (OA)
of the lower limb, with OA being the most
frequent indication for total hip (THR) or
knee replacement (TKR) in the UK1 (over
90% for hips and over 95% for knees). Yet
hip and knee prostheses do not necessarily
continue to function effectively for the life-
time of the patient.1 2 Many traditional
metal-on-polyethylene implants are likely to
require revision surgery due to wear after
20 years of use due to wear characteristics
and peri-prosthetic loosening. As a conse-
quence, elective THR and TKR procedures
have until relatively recently been indicated
mainly in older patients, but even prostheses
which make use of the latest technological
developments (eg, unicondylar knee pros-
theses) are not yet routinely recommended
for use in younger patients.
A further dimension is added by the
increasing prevalence of obesity in western
populations, with clinicians in some cases
Strengths and limitations of this study
▪ The large sample size of the General Practice
Research Database (GPRD; over 5% of the UK
general practice population) enables population-
level inferences to be made.
▪ The statistical methods explicitly account for the
competing risk of death which has a much
higher event rate than the event of interest (total
hip or knee replacement) in this patient group.
▪ GPRD data do not have directly linked informa-
tion detailing the reasons for being referred for
surgery, so we were unable to establish an exact
indication.
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considering patients too obese to undergo surgery,3 4
partly due to the perceived increase in risk of both peri-
operative and postoperative complications. There have
also been examples of obese and/or morbidly obese
patients experiencing restricted access to hip replace-
ment surgery in some parts of the UK5–7 where local
healthcare planners have had similar concerns.
Revision procedures involve a surgical intervention to
correct a prosthesis which is not functioning properly.
Such operations are more costly than the original replace-
ment procedure8 9 and are often more complex, with a
higher level of risk to the patient. Population-based esti-
mates of the time from primary surgery to a revision pro-
cedure are of importance to orthopaedic surgeons,
rheumatologists, healthcare providers, policymakers and
patients. Registry data, both in the UK1 and internation-
ally,10 11 have been used extensively to estimate time to
revision.12 Such data have been used previously to model
prosthesis survival time in order to assess which speciﬁc
demographic, clinical and prosthesis-speciﬁc factors are
associated with time to failure.13 14
Over the 12 months to April 2011, there were over
178 000 THR and TKR operations recorded in the
National Joint Registry (NJR) for England and Wales.1
The NJR began recording data in 2003, and although it
now contains virtually all replacements carried out in
England and Wales, the maximum follow-up is currently
less than 10 years. The registry contains complete data
on many variables, including age and gender, but body
mass index (BMI) is recorded in approximately 61% of
participants undergoing hip replacement (62% for
knee). We chose to use data from a primary care data-
base with long follow-up and UK-wide coverage.
The primary aim of this study was to use data from the
General Practice Research Database (GPRD) to produce
population-based estimates for the association of BMI,
age and gender with the time to revision surgery in the
long term following THR or TKR.
METHOD
Participants
We used data from the GPRD. The GPRD comprises the
entire computerised medical records of a sample of
patients attending general practitioners (GPs) in the UK
covering a population of 6.5 million patients from over
600 contributing practices chosen to be representative
of the wider UK population.15 GPs in the UK play a key
role in the delivery of healthcare by providing primary
care and referral to specialist hospital services. Patients
are registered with one practice that stores medical
information from primary care and hospital atten-
dances. The GPRD has recently become part of the new
Clinical Practice Research Datalink which is adminis-
tered by the Medicines and Healthcare products
Regulatory Agency.
The GPRD records contain all clinical and referral
events in both primary and secondary care in addition
to comprehensive demographic information, prescrip-
tion data and hospital admissions. Data are stored using
read codes for diseases that are cross-referenced to the
International Classiﬁcation of Diseases-9. Read codes are
used as the standard clinical terminology system within
UK primary care. Only practices that pass quality control
are used as part of the GPRD database. Deleting or
encoding personal and clinical identiﬁers ensures the
conﬁdentiality of information in the GPRD. The GPRD
comprises entire general practice populations rather
than probability-based samples of patients.
We identiﬁed all patients in the database with a diagno-
sis code for total hip or knee arthroplasty from the begin-
ning of 1988 until August 2011. We then identiﬁed any
secondary (revision) hip or knee operations for these
patients which occurred subsequent to the primary oper-
ation. The list of Read codes used to identify the primary
and revision operations were independently reviewed by
different clinicians and a consensus list agreed between
them. Deaths recorded within the GPRD were also identi-
ﬁed. The date of the ﬁrst incidence of a patient’s hip or
knee replacement was used as the start time. The event of
interest in all time-to-event models was the ﬁrst recorded
revision operation. Censoring events were the end of study
date (11 August 2011) or the transfer of a patient out of
the GPRD for any reason other than death. Death from
any cause was treated as a competing risk in the primary
analysis. Patients were included in the analysis if aged
18 years or over at the time of the replacement operation.
Participant demographics including age, gender, pre-
operative BMI, smoking and drinking status were collated,
in addition to information on comorbid conditions.
Analysis
We used the competing risks regression methods of Fine
and Gray16 to estimate the effects of a participant’s BMI,
age and gender on the time to revision of a prosthesis
implanted during THR or TKR operation. The substan-
tive event of interest was the ﬁrst incidence of revision
surgery, with all-cause mortality separately identiﬁed as a
competing risk. The rationale for using competing risks
regression is that methods which treat death as just
another censoring event may overestimate risk for an
event of interest, especially in an older population.17 We
adjusted for a range of important covariates and poten-
tial confounders: smoking status, alcohol consumption
and the number of comorbid conditions (which include
diabetes, hypertension, stroke, cardiovascular disease
and anaemia). All covariates were treated as ﬁxed at
baseline. Analyses for hips and knees were performed
separately, with prosthesis survival at the end of follow-up
being of primary interest. Proportionality of hazards
assumptions was assessed by examining complementary
log-log plots of the cumulative incidence. As a sensitivity
analysis we modelled the same data using standard
methods which do not cater for competing risks (ie,
Cox regression analysis with death as a censoring event).
We also calculated stand-alone estimates for the
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cumulative incidence of revision surgery at 1, 5, 10 and
15 years, and plotted estimates of the age-speciﬁc,
gender-speciﬁc and BMI-speciﬁc cumulative incidence
curves for the whole cohort.
All tests of signiﬁcance were at the 5% level and two-
sided. Interval estimates were based on 95% CIs. The
main statistical analysis was carried out using R (R Core
Team, 2012. R Foundation for Statistical Computing,
Vienna, Austria), SAS V.9.2 (SAS Institute Inc, Cary,
North Carolina, USA) and Stata (StataCorp. 2011; Stata




Over the study period the database contained 63 162
patients undergoing THR and 54 276 patients undergo-
ing TKR. The average age at replacement was similar in
both the THR and the TKR groups but the proportion
of women was greater for both THR and TKR (table 1).
For those with a recorded preoperative BMI, the propor-
tion of obese patients (BMI (≥30 kg/m2) was 26.2% for
THR and 39.8% for TKR and the proportion of mor-
bidly obese patients (which we deﬁne as having BMI
(≥40 kg/m2) was 1.6% for THR and 3.6% for TKR.
Eighty per cent of preoperative BMI values used were
recorded within 5 years of the primary operation.
Table 1 describes the baseline characteristics of the
cohort, including summary statistics and missing data
percentages for all explanatory variables where complete
data were not observed.
Survival analysis
The estimated cumulative incidence of revision at
5 years was 2% (95% CI 1.8% to 2.1%) for THR and
1.9% (95% CI 1.8% to 2.1%) for TKR. For women,
cumulative incidence at 5 years was 1.8% (95% CI 1.7%
to 2%) for THR and 1.6% (95% CI 1.5% to 1.8%) for
TKR, and for men 2.2% (95% CI 2% to 2.4%) and 2.3%
(95% CI 2.1% to 2.6%), respectively. Table 2 provides
gender-speciﬁc estimates of cumulative incidence with
point-wise CIs for a range of times (1, 3, 5, 10 and
15 years after THR/TKR). Figures 1 and 2 provide a
further breakdown of the cumulative incidence of revi-
sion for the whole THR and TKR cohorts, respectively,
with separate incidence curves for categorised BMI
(ﬁgure 1) and categorised age (ﬁgure 2). Gray’s test was
used to examine whether there were differences in the
overall cumulative incidence of revision by gender, cate-
gorised age (<55, 55–64, 65–74, 75–84 >85 years) and
Table 1 Clinical and demographic characteristics—all participants undergoing total hip or knee replacement
Total hip replacement (N=63 162) Total knee replacement (N=54 276)
Female (N=39 292) Male (N=23 870) Female (N=31 682) Male (N=22 594)
Age (mean, SD) 70.5 (11.1) 67.7 (11.0) 70.7 (9.6) 69.4 (9.4)
Gender (%) 62.2 37.8 58.3 41.6
BMI (mean, SD) 27.2 (5.1) 27.7 (4.3) 29.6 (5.6) 28.8 (4.4)
Missing BMI (%) 19.1 19.3 13.8 14.0
Revisions (N, %) 1000 (2.55) 811 (3.40) 572 (1.8) 614 (2.7)
Deaths prerevision (N, %) 6615 (16.8) 4201 (17.6) 4110 (13.0) 3349 (14.8)
Number of comorbid conditions (%)
0 42.8 48.1 37.5 43.7
1 34.2 31.0 37.4 35.8
2+ 23.0 20.9 25.2 20.6
BMI, body mass index.
Table 2 Cumulative incidence rates for revision surgery at selected times following THR and TKR
Hip Knee




















1 0.6 (0.5 to 0.6) 0.7 (0.6 to 0.8) 0.3 (0.2 to 0.4) 0.4 (0.3 to 0.5)
3 1.2 (1.1 to 1.3) 1.4 (1.3 to 1.6) 1.1 (1.0 to 1.2) 1.5 (1.4 to 1.7)
5 1.8 (1.7 to 2.0) 2.2 (2.0 to 2.4) 1.6 (1.5 to 1.8) 2.3 (2.1 to 2.6)
10 3.4 (3.1 to 3.6) 4.6 (4.3 to 5.0) 2.8 (2.5 to 3.1) 4.5 (4.1 to 4.9)
15 6.0 (5.5 to 6.6) 8.3 (7.6 to 9.1) 4.4 (3.9 to 5.0) 7.1 (6.2 to 8.1)
THR, total hip replacement; TKR, total knee replacement.
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categorised BMI (<18.5, 18.5–24.9, 25–29.9, 30–39.9 and
>40 kg/m2). All three variables showed statistically sig-
niﬁcant differences in cumulative incidence for both hip
(Gray’s test statistic: gender, age, BMI, p<0.001 for all)
and knee (Gray’s test statistic: gender, age, BMI, p<0.001
for all).
In a single predictor (univariable) survival model allow-
ing for the competing risk of death over the entire period
of follow-up, we estimated that THR participants had a 3%
increase in the subhazard of revision (SHR 1.030, 95% CI
1.020 to 1.041, p<0.001) for each extra unit (kg/m2) of
BMI, with TKR participants showing a 2.6% increase per
unit (SHR 1.026, 95% CI 1.013 to 1.038, p<0.001). The
SHR was signiﬁcantly greater for men compared with
women for both THR (subhazard ratio (SHR)): 1.35, 95%
CI 1.23 to 1.48, p<0.001) and TKR 2% (SHR 1.54, 95% CI
1.37% to 1.72%, p<0.001). Age at total joint replacement
was also a signiﬁcant univariable predictor of revision for
both hip and knee, with THR participants estimated to
have a 3% reduction in the SHR (0.970, 95% CI 0.967 to
0.973, p<0.001) for each extra year of age, with TKR parti-
cipants showing a 4.3% reduction (SHR 0.957, 95% CI
0.952% to 0.961%, p<0.001).
The effects for all three variables (gender, age and
BMI) were then estimated in multivariable competing
risks regression models after adjusting for smoking
status, drinking status and the number of comorbid con-
ditions, again over the entire period of follow-up. For
age, the estimates for the SHR were almost exactly the
same as those from the univariable model for both hip
and knee, but for gender (SHR 1.23 for hip; 1.51 for
knee) and BMI (SHR 1.020 for hip; 1.015 for knee) the
estimates were smaller. Nevertheless, all three variables
remained statistically signiﬁcant for both hip and knee
in the presence of adjustment. For a 5-unit and 10-unit
increase in BMI, this represents an increase in THR revi-
sion risk of 10.4% and 21.9%, respectively (7.7% and
16.1% for TKR).Testing for two-way interactions between
age, gender and BMI did not produce any signiﬁcant
Figure 1 Cumulative incidence estimate for revision of (A)
total hip replacement (B) total knee replacement by body
mass index.
Figure 2 Cumulative incidence estimate for revision of (A)
total hip replacement (B) total knee replacement by age.
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effects. All subhazard estimates (with 95% CIs and p
values) from the univariable and multivariable models
are given in tables 3 and 4.
To further explore the effect estimates for BMI we ran
the same adjusted age-gender-BMI model described
above, but used categorical BMI instead of continuous.
For morbidly obese TKR participants (BMI 40+) there
was a 43.9% increase (95% CI 2.6% to 103.9%, p=0.040)
in the SHR compared with those with a normal BMI
(18.5–25), but the effect for THR was larger (a 65.5%
increase) and stronger (95% CI 15.4% to 137.3%,
p=0.006). The effect sizes were similar to those obtained
when using the adjusted sub-HR estimate of continuous
BMI for a participant with a BMI of 45 relative to one
with a BMI of 22 (increase of 57.7% for THR; 40.8% for
TKR). For obese patients in the range 30–40 kg/m2
versus those with a normal BMI, the estimated sub-HR for
revision was weakly signiﬁcant for THR (15.7% increase,
95% CI 0.2% to 33.7%, p=0.048) but not for TKR (17.9%
increase, 95% CI −1.9% to 41.6%, p=0.079).
As a sensitivity analysis, we also performed standard Cox
regressions with revision surgery as the event of interest
and where no distinction was made between death and
other censoring events. Univariable models for age,
gender and BMI gave very similar results to the competing
risks analysis, as did the multivariable models which
adjusted for the same factors as in the competing risks
regression. Results from the Cox regression models are
given in tables 5 and 6. In addition, we calculated that it
would take 175 patients with TKR to reduce their baseline
BMI from obese to normal in order to prevent one
revision operation after 5 years. For patients with THR this
number reduces to 152.
Finally, we assessed whether the higher incidence of hip
revision surgery during the ﬁrst year following THR (see
ﬁgures 1A and 2A) might compromise the proportionality
assumption and therefore suggest the inclusion of time-
dependent effects. Separate univariable piecewise compet-
ing risk models for hip revision were ﬁtted for gender, age
(≤65 years vs >65) and BMI (>40 vs ≤40). A single change
point at 1 year was used to simultaneously estimate two
sub-HRs for revision (before and after 1 year following
THR). The only model which provided some evidence for
a different sub-HR during the ﬁrst year was with BMI (>40
vs ≤40) as the predictor (SHR 2.619, 95% CI 1.502 to
4.560, p=0.001), but this was not matched with a statistic-
ally signiﬁcant estimate for revision after the ﬁrst year
(SHR 0.575, 95% CI 0.238 to 1.170, p=0.130).
DISCUSSION
This study presents population-based estimates for the
risk of revision following total joint replacement of the
hip and knee using methods from survival analysis.
Cumulative incidence rates of revision were higher for
men than for women and higher for hips than knees.
Age, gender and BMI were estimated to be signiﬁcant
predictors of time to revision in an adjusted model
allowing for the competing risk of death. Severely obese
patients undergoing THR were observed to have a
higher risk of revision surgery during the ﬁrst year
Table 3 Estimated subhazard of revision for total hip replacement—competing risks analysis
Univariable Adjusted*
HR 95% CI p Value HR 95% CI p Value
BMI† (kg/m2) (per additional unit) 1.030 (1.020 to 1.041) <0.001 1.020 (1.009 to 1.032) <0.001
Gender
Female (reference) 1.00 1.00 (1.10 to 1.38) <0.001
Male 1.35 (1.23 to 1.48) <0.001 1.23
Age (years at THR) (per additional year) 0.970 (0.967 to 0.973) <0.001 0.971 (0.966 to 0.975) <0.001
*Adjusted for smoking (yes/no/ex), drinking (yes/no/ex), number of comorbid conditions.
†BMI available in 86.1% of patients.
BMI, body mass index; THR, total hip replacement.
Table 4 Estimated subhazard of revision for total knee replacement—competing risks analysis
Univariable Adjusted*
HR 95% CI p Value HR 95% CI p Value
BMI† (kg/m2) (per additional unit) 1.026 (1.013 to 1.038) <0.001 1.015 (1.002 to 1.028) 0.023
Gender
Female (reference) 1.00 1.00 (1.32 to 1.73) <0.001
Male 1.54 (1.37 to 1.72) <0.001 1.51
Age (years at THR) (per additional year) 0.957 (0.952 to 0.961) <0.001 0.957 (0.951 to 0.962) <0.001
*Adjusted for smoking (yes/no/ex), drinking (yes/no/ex), number of comorbid conditions.
†BMI available in 80.9% of patients.
BMI, body mass index; THR, total hip replacement.
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following replacement, but the same effect was not
observed for knee replacement.
The literature on obesity as a risk factor for hip and
knee arthroplasty concentrates mainly on the risk for
primary replacement rather than for revision procedures,
and most use rate differences to estimate relative risk,
rather than using time-to-event methods. Many published
studies are small and do not have sufﬁcient power to
detect rare outcomes. Often these studies are locally based
and the generalisability to population level is questionable.
Mostly results are presented for categorised BMI, which is
often dichotomised at 30 kg/m2, and where results for the
morbidly obese are reported, the sample size is small.
One of the largest studies examining primary replace-
ment followed up a cohort of over 490 000 middle-aged
women over an average of 2.9 years and found increased
incidence of hip and knee replacement in obese partici-
pants.18 Of the studies which consider the effect of obesity
on outcomes after primary joint replacement, several
focus mainly on events such as complications arising from
surgery19 or subsequent admission to an intensive care
unit,20 rather than the time to revision surgery. Among
studies of other non-revision outcomes, Andrew et al21
looked at the change in Oxford Hip Score 5 years after
THR and found no difference between non-obese, obese
and morbidly obese patients, but in a smaller study22 using
Harris Hip Score (HHS) with the same length of
follow-up, an increase in BMI was associated with a small
but signiﬁcant reduction in HHS.
An editorial on obesity and joint replacement in
200623 suggested that it is those with BMI of greater
than 40 units (rather than 30) who are at risk of worse
outcomes, yet several subsequent studies have used a
BMI cut-point of 30 kg/m2. A recent Australian study of
2026 patients with THR and 535 with TKR found no dif-
ference in mid-term survival rates between the obese
(BMI > 30 kg/m2) and non-obese.24 Another study from
Switzerland used Cox regression to estimate the risk of
revision in 2495 THRs using the same cut-point for BMI,
estimating a non-signiﬁcant adjusted HR for revision of
2.2 (95% CI 0.9 to 5.3) for obese versus non-obese
patients.19 However, a recent Canadian study of 3290
THRs did categorise BMI to include a morbidly obese
group (BMI>40 kg/m2) and although the authors found
no difference in time to revision between BMI categories
in an unadjusted analysis, there was a marginally signiﬁ-
cant difference for septic revisions.25
Our results suggest that there may be a 1.5–2% rise in
the risk of knee and hip revision, respectively, for each
extra unit of BMI. However, there is some variation in
risk across the entire range of observed BMI values. For
hips, there appears to be very little difference in
BMI-related risk between the normal weight and over-
weight categories. However, ﬁgure 1A shows that for hips
there may be a revision rate of approximately 6% for the
morbidly obese after 10 years, against a 3% rate for the
normal and overweight. For knees, ﬁgure 1B shows a
more even distribution across the BMI categories up to
Table 5 Estimated hazard of revision for THR—univariable and adjusted Cox regression analysis with death as a censoring
event
Univariable Adjusted*
HR 95% CI p Value HR 95% CI p Value
BMI† (kg/m2) (per additional unit) 1.029 (1.017 to 1.040) <0.001 1.019 (1.008 to 1.031) 0.001
Gender
Female (reference) 1.00 1.00 <0.001
Male 1.36 (1.24 to 1.29) <0.001 1.26 (1.13 to 1.41)
Age (years at THR) (per additional year) 0.978 (0.974 to 0.983) <0.001 0.977 (0.972 to 0.982) <0.001
*Adjusted for smoking (yes/no/ex), drinking (yes/no/ex), number of comorbid conditions.
†BMI available in 86.1% of patients.
BMI, body mass index; THR, total hip replacement.
Table 6 Estimated hazard of revision for TKR—univariable and adjusted Cox regression analysis with death as a censoring
event
Univariable Adjusted*
HR 95% CI p Value HR 95% CI p Value
BMI† (kg/m2) (per additional unit) 1.024 (1.012 to 1.037) <0.001 1.015 (1.003 to 1.028) 0.019
Gender
Female (reference) 1.00 1.00 <0.001
Male 1.58 (1.41 to 1.77) <0.001 1.55 (1.36 to 1.77)
Age (years at THR) (per additional year) 0.962 (0.956 to 0.967) <0.001 0.961 (0.955 to 0.968) <0.001
*Adjusted for smoking (yes/no/ex), drinking (yes/no/ex), number of comorbid conditions.
†BMI available in 80.9% of patients.
BMI, body mass index; THR, total hip replacement; TKR, total knee replacement.
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about 7 years after TKR, but with higher risk for the
morbidly obese between 7 and 10 years after TKR.
Although recommendations26 27 to consider the use
of the cumulative incidence function for analysing pros-
thesis survival are gaining acceptance,28 the use of com-
peting risks regression to model associated risk factors is
still not widely observed. The justiﬁcation for using com-
peting risks methods in our primary analysis is that hip
and knee prostheses are mainly implanted in older
patients for whom mortality is a substantial competing
risk which may be several times greater than the risk of
revision. What is perhaps surprising is that our results
show little difference between the HR and sub-HR esti-
mates from the Cox and the competing risks regression
models, respectively, although the former has a cause-
speciﬁc interpretation with no distinction between death
and censoring whereas the latter directly models the
cumulative incidence of revision.
Strengths and potential limitations of the study
The strengths of the study data more than the make up for
its limitations. GPRD data have individual date-stamped
records of patient event data in primary and secondary
care settings, including data on many potential confoun-
ders, including comorbidities, BMI, smoking and drink-
ing. The GPRD practice network covers all of the UK, and
approximately 5% of all practices are covered by the
GPRD. The high degree of generalisability afforded by this
very large sample enables population-level inferences to
be made. Follow-up is long, with several hundred pros-
theses in the dataset having over 20 years of follow-up
without being revised. The choice of the statistical
methods used to allow for the competing risk of death
adds a further degree of robustness to the study. The
regression estimates of the HR for BMI as a factor asso-
ciated with revision beneﬁt from a precision which is not
usually achievable outside of national registers, especially
for the group of morbidly obese patients within which
event rates in the literature are low.
There are several limitations to this work. The revision
rate estimates hip and knee at 5 years are close to, but
slightly less than those reported by the NJR, but the
GPRD data used in this study include prostheses
implanted from the late 1980s. Also our data do not
have directly linked information on the indication for
surgery, which would have been enabled a subanalysis by
reason for revision. Although certain indications for revi-
sion are more common than others depending on
follow-up time (eg, infection occurring early), any infer-
ences about indication-speciﬁc risks before or after a
given follow-up time would not have been reliable.
CONCLUSION
This study has presented estimates of rates and risk
factors for revision surgery on hip and knee prostheses
using one of the largest available population-based sets
of joint replacement data outside of national
arthroplasty registries. Our estimates suggest that BMI is
positively associated with the risk of hip and knee revi-
sion, but studies of register data linked with sources of
demographic and clinical data are needed in order to
distinguish between effects for speciﬁc indications for
revision surgery.
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